术前应用洛铂联合紫杉醇新辅助化疗方案对局部宫颈癌晚期患者的疗效及预后研究  

The Curative Effects of Combined Neoadjuvant Chemotherapy of Paclitaxel and Lobaplatin for Locally Advanced Cervical Carcinoma Patients before Operation

作　　者：柯丽娟[1] 孙阳[1] 刘佳华[1] 宋保志[1] 林飞峰[1] KE Lijuan SUN Yang LIU Jiahua SONG Baozhi LIN Feifeng(Department of Gynecology, Provincial Clinical College of Fujian Medical University/Fujian Provincial Hospital, Fuzhou, Fujian, 350001, China)

机构地区：[1]福建医科大学省立临床学院/福建省立医院妇科,福建福州350001

出　　处：《肿瘤药学》2016年第6期442-445,450,共5页Anti-Tumor Pharmacy

基　　金：福建省自然科学基金资助项目(No.2016J01503)

摘　　要：目的探讨宫颈癌晚期患者术前应用洛铂联合紫杉醇新辅助化疗方案(TP方案)的疗效及预后。方法选取2011年6月至2013年6月在我院进行术前新辅助化疗的86例局部晚期宫颈癌患者,采用随机数字表法分为TP组、FP组,每组各43例。TP组患者给予洛铂联合紫杉醇术前新辅助化疗,FP组患者给予氟尿嘧啶联合顺铂术前新辅助化疗。对比两组患者的化疗近期疗效、手术情况、化疗前后肿瘤标记物及化疗毒副作用发生率。结果 TP组总有效率为76.74%,显著高于FP组的53.48%(P<0.05);TP组手术时间、出血量、阴道切缘阳性率、盆腔淋巴结转移率与FP组比较,差异均无统计学意义(P>0.05);TP组患者3年复发率为20.93%,显著低于FP组的44.19%(P<0.05),TP组3年生存率(81.40%)与FP组(72.09%)比较,差异无统计学意义(P>0.05);化疗过程中,TP组与FP组的毒副反应发生率无显著差异(P>0.05)。结论洛铂联合紫杉醇新辅助化疗对局部晚期宫颈癌患者的疗效优于氟尿嘧啶联合顺铂。Objective To study the curative effect of combined neoadjuvant chemotherapy of paclitaxel and lobaplatin for locally advanced cervical carcinoma patients hefore operation. Methods 86 patients with locally advanced cervical carcinoma were selected for preoperative neoadjuvant chemotherapy research from June 2011 to June 2013 in our hospital. They were divided into TP group and FP group, 43 cases for each group. Patients in TP group were given paelitaxel and lobaplatin and those in FP group fluorouracil and cisplatin. Compare the curative effect, operation condition, prognosis, tumor markers and the incidence of adverse drug reactions between the two groups. Results The total effective rate of TP group was 76.74%, higher than that of FP group （53.48%）, and the difference was statistically significant （P 〈 0.05）. However, there were no statistically significant differences in operation time, amount of operative bleeding, positive rate of vaginal cut edge, metastasis rate of pelvic lymph node between TP group and FP group （P〉0.05）. TP group had a 3-year recurrence rate of 20.93%, less than FP group which had 44.19% （P〈0.05）. The 3-year survival rates of TP group and FP group were respectively 81.40% and 72.09% （P 〉 0.05）. During chemotherapy, the incidence of adverse reaction in TP and FP group had no statistically significant difference （P〉 0.05）. Conclusion The curative effect of combined neoadjuvant chemotherapy of paclitaxel and lobaplatin was better than that of FP group for locally advanced cervical carcinoma patients before operation,

关 键 词：洛铂 紫杉醇 新辅助化疗 局部宫颈癌晚期 

分 类 号：R737.33[医药卫生—肿瘤]